SCHEMBL10326340

SCHEMBL10326340

Cc1ccc(C(O[Si](C)(C)C)(c2ccc(C)cc2)C2CCCN2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CHRM2 P08172 3/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
SCN10A Q9Y5Y9 1/20 0.31
CHRNB2 P17787 2/20 0.31
CHRNA4 P43681 1/20 0.31
CHRNA5 P30532 1/20 0.30
CHRNB4 P30926 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17676911 0.95 CYP2D6 (0.50) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL10326947 0.88 HPGD (0.41) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL1447193 0.87 CYP2D6 (0.56) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL3004482 0.87 CYP2D6 (0.56) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL2574515 0.87 CYP2D6 (0.56) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL3008935 0.85 KDM4E (0.38) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL5523455 0.85 KDM4E (0.38) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL12996884 0.85 KDM4E (0.35) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL10326634 0.85 KDM4E (0.35) CYP1A2CYP2D6CYP2C19KDM4ENPC1
SCHEMBL10326342 0.85 KDM4E (0.35) CYP1A2CYP2D6CYP2C19KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed
WO-2010140636-A1 ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 CYP1A2 1183/4885CYP2D6 1125/4885CYP2C19 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.